Cancer-related cognitive impairment (CRCI), depression and quality of life in gynecological cancer patients: a prospective study

Rosa, Nicoletta De; Corte, Luigi Della; Giannattasio, Alessia; Giampaolino, Pierluigi; Carlo, Costantino Di; Bifulco, Giuseppe

doi:10.1007/s00404-020-05896-6

Cited by 27 publications

(18 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Most of the studies on cognitive changes in non-CNS cancers investigate women with breast cancer treated with chemotherapy, but recently patients with other malignancies have also been intensively studied. Cognitive impairment has been reported in patients with colorectal cancer ( Cruzado et al, 2014 ; Vardy et al, 2015 ), lung cancer ( Simo et al, 2015 ; Bromis et al, 2017 ), testicular cancer ( Schagen et al, 2008 ; Wefel et al, 2014 ; Stouten-Kemperman et al, 2015 ; Amidi et al, 2017b ; Chovanec et al, 2018 ), prostate cancer ( McGinty et al, 2014 ; Gonzalez et al, 2015 ; Holtfrerich et al, 2020 ), ovarian cancer and other gynecological malignancies ( Hess et al, 2015 ; Correa et al, 2017 ; De Rosa et al, 2021 ), as well as hematologic malignancies, especially after hematopoietic stem cell transplantation (HSCT) ( Scherwath et al, 2013 ; Sharafeldin et al, 2018 ).…”

Section: Introductionmentioning

confidence: 99%

Long-Term Cognitive Dysfunction in Cancer Survivors

Országhová

Mego

Chovanec

2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Cancer-related cognitive impairment (CRCI) is a frequent side effect experienced by an increasing number of cancer survivors with a significant impact on their quality of life. Different definitions and means of evaluation have been used in available literature; hence the exact incidence of CRCI remains unknown. CRCI can be described as cognitive symptoms reported by cancer patients in self-reported questionnaires or as cognitive changes evaluated by formal neuropsychological tests. Nevertheless, association between cognitive symptoms and objectively assessed cognitive changes is relatively weak or absent. Studies have focused especially on breast cancer patients, but CRCI has been reported in multiple types of cancer, including colorectal, lung, ovarian, prostate, testicular cancer and hematological malignancies. While CRCI has been associated with various treatment modalities, including radiotherapy, chemotherapy, hormone therapy and novel systemic therapies, it has been also detected prior to cancer treatment. Therefore, the effects of cancer itself with or without the psychological distress may be involved in the pathogenesis of CRCI as a result of altered coping mechanisms after cancer diagnosis. The development of CRCI is probably multifactorial and the exact mechanisms are currently not completely understood. Possible risk factors include administered treatment, genetic predisposition, age and psychological factors such as anxiety, depression or fatigue. Multiple mechanisms are suggested to be responsible for CRCI, including direct neurotoxic injury of systemic treatment and radiation while other indirect contributing mechanisms are hypothesized. Chronic neuroinflammation mediated by active innate immune system, DNA-damage or endothelial dysfunction is hypothesized to be a central mechanism of CRCI pathogenesis. There is increasing evidence of potential plasma (e.g., damage associated molecular patterns, inflammatory components, circulating microRNAs, exosomes, short-chain fatty acids, and others), cerebrospinal fluid and radiological biomarkers of cognitive dysfunction in cancer patients. Discovery of biomarkers of cognitive impairment is crucial for early identification of cancer patients at increased risk for the development of CRCI or development of treatment strategies to lower the burden of CRCI on long-term quality of life. This review summarizes current literature on CRCI with a focus on long-term effects of different cancer treatments, possible risk factors, mechanisms and promising biomarkers.

show abstract

Section: Introductionmentioning

confidence: 99%

Long-Term Cognitive Dysfunction in Cancer Survivors

Országhová

Mego

Chovanec

2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…The high patient satisfaction should be weighed against the low cost of $50 for each ACP ® double syringe system. It is important to consider that improving quality of life may counteract cancer-related cognitive impairment for cancer survivors [ 17 , 18 ]. The use of PRP should at least be considered and offered to patients.…”

Section: Discussionmentioning

confidence: 99%

Platelet-rich plasma (PRP) in oncological patients: long-term oncological outcome analysis of the treatment of subcutaneous venous access device scars in 89 breast cancer patients

Eichler

Üner

Thangarajah

et al. 2022

Arch Gynecol Obstet

View full text Add to dashboard Cite

Purpose Platelet-rich plasma (PRP) is widely used product, and meta-analyses showed this product to be beneficial when applied to a wound area. This study group has already demonstrated increased patient satisfaction and lower complication rates in breast cancer patients who received PRP after removal of their subcutaneous venous access device. This work is a follow-up analysis focusing on oncologic safety. Currently, there is no long-term data on the use of PRP products in cancer patients available yet. Methods Between the years 2012–2016, venous access device removal was supported with the application of Arthrex ACP® (Autologous Conditioned Plasma)—a PRP product to improve the wound-healing process. All surgeries were performed in the breast cancer center of the municipal hospital of Cologne, Holweide, Germany. 35 patients received an application of Arthrex ACP® after port removal compared to the control group of 54 patients. Endpoints were local recurrence-free, distant recurrence-free as well as overall survival. Results Median follow-up was 45 months. No (0) adverse events were shown for cancer recurrence within the subcutaneous venous access device scar area. Thus, there seems to be no local oncogenic potential of the PRP product. All other endpoints as well as any-cause death numerically favor PRP use. Conclusion PRP products such as Arthrex ACP® seem to be oncological inert when applied after removal of subcutaneous access devices. This is the first study providing long-term data about overall survival, distant recurrence-free and local recurrence-free survival after applying PRP in high-risk cancer patients.

show abstract

“…Vulnerability to depression is increased across the menopause transition. Surgical menopause due to cancer treatment increases depression even further in ovarian cancer patients [21].…”

Section: Purposementioning

confidence: 99%

Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database

Bossart

Plett

Krämer³

et al. 2022

Arch Gynecol Obstet

View full text Add to dashboard Cite

Introduction The intention of this study was to evaluate the level of anxiety and depression of malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST) survivors and to identify possible alterable cofactors. Methods CORSETT was an observational, multicenter, mixed retrospective/prospective cohort study of the AGO Studygroup. Women who had been diagnosed with MOGCTs and SCSTs between 2001 and 2011 were asked to complete the Hospital Anxiety and Depression Scale (HADS) to evaluate distress. Predictors of distress (type of surgery, chemotherapy, time since diagnosis, recurrence, second tumor, pain) were investigated using multivariate linear regression analysis. Results 150 MOGCT and SCST patients with confirmed histological diagnosis completed the questionnaire median seven years after diagnosis. They had a HADS total score ≥ 13 indicating severe mental distress in 34% of cases. Patients after fertility-conserving surgery had lower probability of severe mental distress than those without fertility-conserving treatment (β = − 3.1, p = 0.04). Pain was associated with the level of distress in uni- and multivariate analysis (coef 0.1, p < 0.01, coef. Beta 0.5). Discussion Severe mental distress was frequent in patients with MOGCT and SCST and the level of pain was associated with the level of distress. Fertility conserving therapy, however, was associated with less mental distress. Screening and treatment of pain and depression is required to improve mental well-being in survivors of MOGCT and SCST.

show abstract

Cancer-related cognitive impairment (CRCI), depression and quality of life in gynecological cancer patients: a prospective study

Cited by 27 publications

References 35 publications

Long-Term Cognitive Dysfunction in Cancer Survivors

Long-Term Cognitive Dysfunction in Cancer Survivors

Platelet-rich plasma (PRP) in oncological patients: long-term oncological outcome analysis of the treatment of subcutaneous venous access device scars in 89 breast cancer patients

Depression and anxiety in women with malignant ovarian germ cell (MOGCT) and sex cord stromal tumors (SCST): an analysis of the AGO-CORSETT database

Contact Info

Product

Resources

About